β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
14
02
2022
accepted:
08
06
2022
revised:
07
06
2022
pubmed:
21
6
2022
medline:
16
9
2022
entrez:
20
6
2022
Statut:
ppublish
Résumé
The association between use of β-blockers and breast cancer (BC) prognosis has been investigated in several observational studies, with conflicting results. We performed a nationwide cohort study and a meta-analysis to investigate the association, and assess if it varied between molecular subtypes of BC. We identified women aged ≥50 years with BC diagnosed between 2004 and 2018 in Norway. We used Cox regression models to estimate the association between β-blocker use at diagnosis and BC-specific survival, overall and by molecular subtype. We performed a meta-analysis of observational studies that reported molecular subtype-specific estimates of this association. We included 30,060 women, of which 4461 (15%) used β-blockers. After a median follow-up of 5.1 years, 2826 (9%) died of BC. Overall, β-blocker use was not associated with BC-specific survival (hazard ratio [HR] = 1.07; 95% confidence interval [CI]: 0.97-1.19). We found an association only in triple-negative BC (TNBC) patients (HR = 0.66; 95% CI: 0.47-0.91). This was confirmed in the meta-analysis: β-blocker use was associated with progression/recurrence-free (HR = 0.58; 95% CI: 0.38-0.89) and BC-specific survival (HR = 0.74; 95% CI: 0.55-1.00) in TNBC patients only. In our cohort of BC patients and in the meta-analysis, β-blocker use was associated with prolonged BC-specific survival only in TNBC patients.
Sections du résumé
BACKGROUND
The association between use of β-blockers and breast cancer (BC) prognosis has been investigated in several observational studies, with conflicting results. We performed a nationwide cohort study and a meta-analysis to investigate the association, and assess if it varied between molecular subtypes of BC.
METHODS
We identified women aged ≥50 years with BC diagnosed between 2004 and 2018 in Norway. We used Cox regression models to estimate the association between β-blocker use at diagnosis and BC-specific survival, overall and by molecular subtype. We performed a meta-analysis of observational studies that reported molecular subtype-specific estimates of this association.
RESULTS
We included 30,060 women, of which 4461 (15%) used β-blockers. After a median follow-up of 5.1 years, 2826 (9%) died of BC. Overall, β-blocker use was not associated with BC-specific survival (hazard ratio [HR] = 1.07; 95% confidence interval [CI]: 0.97-1.19). We found an association only in triple-negative BC (TNBC) patients (HR = 0.66; 95% CI: 0.47-0.91). This was confirmed in the meta-analysis: β-blocker use was associated with progression/recurrence-free (HR = 0.58; 95% CI: 0.38-0.89) and BC-specific survival (HR = 0.74; 95% CI: 0.55-1.00) in TNBC patients only.
CONCLUSION
In our cohort of BC patients and in the meta-analysis, β-blocker use was associated with prolonged BC-specific survival only in TNBC patients.
Identifiants
pubmed: 35725814
doi: 10.1038/s41416-022-01891-7
pii: 10.1038/s41416-022-01891-7
pmc: PMC9470740
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1096Informations de copyright
© 2022. The Author(s).
Références
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Sebuødegård S, Botteri E, Hofvind S. Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway. J Natl Cancer Inst. 2019;112:839–46.
doi: 10.1093/jnci/djz220
Cancer Registry of Norway. Cancer in Norway 2020—Cancer incidence, mortality, survival and prevalence in Norway. Oslo, Norway: Caner Registry of Norway; 2021.
Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort. Int J Cancer. 2019;144:1251–61.
pubmed: 30367449
doi: 10.1002/ijc.31950
Nissen MD, Sloan EK, Mattarollo SR. β-Adrenergic signaling impairs antitumor CD8+ T-cell responses to B-cell lymphoma immunotherapy. Cancer Immunol Res. 2018;6:98–109.
pubmed: 29146881
doi: 10.1158/2326-6066.CIR-17-0401
Mohammadpour H, MacDonald CR, McCarthy PL, Abrams SI, Repasky EA. β2-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME. Cell Rep. 2021. https://doi.org/10.1016/j.celrep.2021.109883 .
Le CP, Nowell CJ, Kim-Fuchs C, Botteri E, Hiller JG, Ismail H, et al. Chronic stress in mice remodels lymph vasculature to promote tumour cell dissemination. Nature Commun. 2016. https://doi.org/10.1038/ncomms10634 .
Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12:939–44.
pubmed: 16862152
doi: 10.1038/nm1447
Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70:7042–52.
pubmed: 20823155
doi: 10.1158/0008-5472.CAN-10-0522
pmcid: 2940980
Chang A, Le CP, Walker AK, Creed SJ, Pon CK, Albold S, et al. 2-Adrenoceptors on tumor cells play a critical role in stress-enhanced metastasis in a mouse model of breast cancer. Brain Behav Immun. 2016;57:106–15.
pubmed: 27321906
doi: 10.1016/j.bbi.2016.06.011
pmcid: 5060133
Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18:1201–6.
pubmed: 22186256
doi: 10.1158/1078-0432.CCR-11-0641
Gillis RD, Botteri E, Chang A, Ziegler AI, Chung NC, Pon CK, et al. Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. Eur J Cancer. 2021;147:106–16.
pubmed: 33639323
doi: 10.1016/j.ejca.2021.01.029
Zhong S, Yu D, Zhang X, Chen X, Yang S, Tang J, et al. β-Blocker use and mortality in cancer patients: systematic review and meta-analysis of observational studies. Eur J Cancer Prev. 2016;25:440–8.
pubmed: 26340056
doi: 10.1097/CEJ.0000000000000192
Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2645–52.
pubmed: 21632501
doi: 10.1200/JCO.2010.33.4441
pmcid: 3139371
Sørensen GV, Ganz PA, Cole SW, Pedersen LA, Sørensen HT, Cronin-Fenton DP, et al. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol. 2013;31:2265–72.
pubmed: 23650417
doi: 10.1200/JCO.2012.43.9190
pmcid: 3677839
Cardwell CR, Coleman HG, Murray LJ, Entschladen F, Powe DG. Beta-blocker usage and breast cancer survival: a nested case-control study within a UK Clinical Practice Research Datalink cohort. Int J Epidemiol. 2013;42:1852–61.
pubmed: 24536096
doi: 10.1093/ije/dyt196
Spera G, Fresco R, Fung H, Dyck JRB, Pituskin E, Paterson I, et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Ann Oncol. 2017;28:1836–41.
pubmed: 28520849
doi: 10.1093/annonc/mdx264
Modi ND, Tan JQE, Rowland A, Koczwara B, Kichenadasse G, McKinnon RA, et al. The influence of pre-existing beta-blockers use on survival outcomes in HER2 positive advanced breast cancer: pooled analysis of clinical trial data. Front Oncol. 2020. https://doi.org/10.3389/fonc.2020.01130 .
Lorona NC, Cook LS, Tang M-TC, Hill DA, Wiggins CL, Li CI. Antihypertensive medications and risks of recurrence and mortality in luminal, triple-negative, and HER2-overexpressing breast cancer. Cancer Causes Control. 2021;32:1375–84.
pubmed: 34347212
doi: 10.1007/s10552-021-01485-3
Santala EEE, Murto MO, Artama M, Pukkala E, Visvanathan K, Murtola TJ. Angiotensin receptor blockers associated with improved breast cancer survival—a nationwide cohort study from Finland. Cancer Epidemiol Biomark Prev. 2020;29:2376–82.
doi: 10.1158/1055-9965.EPI-20-0711
Norwegian Tax Agency. Personal Identification Number. 2021. https://www.skatteetaten.no/en/person/foreign/norwegian-identification-number/what-is-an-identification-number/ . Accessed 2021-08-02.
Larsen IK, Smastuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, et al. Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45:1218–31.
pubmed: 19091545
doi: 10.1016/j.ejca.2008.10.037
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathol. 1991;19:403–10.
doi: 10.1111/j.1365-2559.1991.tb00229.x
Sisti JS, Collins LC, Beck AH, Tamimi RM, Rosner BA, Eliassen AH. Reproductive risk factors in relation to molecular subtypes of breast cancer: Results from the nurses’ health studies. Int J Cancer. 2016;138:2346–56.
pubmed: 26684063
doi: 10.1002/ijc.29968
pmcid: 5245093
National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. 2021. https://seer.cancer.gov/ Accessed 2021-12-01.
American Joint Committee on Cancer. AJCC cancer staging manual. 7th edn. New York, USA: Springer Verlag New York Inc; 2010.
Furu, K Establishment of the nationwide Norwegian Prescription Database (NorPD)–new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiol. 2009;18. https://doi.org/10.5324/nje.v18i2.23 .
Norwegian Institute of Public Health. Norwegian Cause of Death Registry. 2020. https://www.fhi.no/hn/helseregistre-og-registre/dodsarsaksregisteret/dodsarsaksregisteret2/ . Accessed 2021-06-04.
Statistics Norway. https://www.ssb.no/en . 2021. Accessed 2021-12-01.
Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2:797–809.
pubmed: 22006582
doi: 10.18632/oncotarget.343
pmcid: 3248157
Reeder A, Attar M, Nazario L, Bathula C, Zhang A, Hochbaum D, et al. Stress hormones reduce the efficacy of paclitaxel in triple negative breast cancer through induction of DNA damage. Br J Cancer. 2015;112:1461–70.
pubmed: 25880007
doi: 10.1038/bjc.2015.133
pmcid: 4453678
Korzeniowski S, Dyba T. Reproductive history and prognosis in patients with operable breast cancer. Cancer. 1994;74:1591–4.
pubmed: 8062190
doi: 10.1002/1097-0142(19940901)74:5<1591::AID-CNCR2820740515>3.0.CO;2-#
Zhai Z, Zhang F, Zheng Y, Zhou L, Tian T, Lin S, et al. Effects of marital status on breast cancer survival by age, race, and hormone receptor status: a population-based Study. Cancer Med. 2019;8:4906–17.
pubmed: 31267686
doi: 10.1002/cam4.2352
pmcid: 6712463
Lundqvist A, Andersson E, Ahlberg I, Nilbert M, Gerdtham U. Socioeconomic inequalities in breast cancer incidence and mortality in Europe-a systematic review and meta-analysis. Eur J Public Health. 2016;26:804–13.
pubmed: 27221607
doi: 10.1093/eurpub/ckw070
pmcid: 5054273
Cronin-Fenton DP, Nørgaard M, Jacobsen J, Garne JP, Ewertz M, Lash TL, et al. Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer. 2007;96:1462–8.
pubmed: 17406360
doi: 10.1038/sj.bjc.6603717
pmcid: 2360185
van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw 2011;45:1–67.
doi: 10.18637/jss.v045.i03
van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med. 2002;21:589–624.
pubmed: 11836738
doi: 10.1002/sim.1040
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
pubmed: 12111919
doi: 10.1002/sim.1186
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
pubmed: 9310563
doi: 10.1136/bmj.315.7109.629
pmcid: 2127453
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2008. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp . Accessed 2022-01-07.
Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29:2635–44.
pubmed: 21632503
doi: 10.1200/JCO.2010.33.5422
Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJA, Fujii M, et al. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014;144:405–16.
pubmed: 24557337
doi: 10.1007/s10549-014-2870-5
pmcid: 3988288
Cardwell CR, Pottegård A, Vaes E, Garmo H, Murray LJ, Brown C, et al. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts. Breast Cancer Res. 2016;18:119.
pubmed: 27906047
doi: 10.1186/s13058-016-0782-5
pmcid: 5133766
Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, et al. Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J Cancer. 2013;4:549–56.
pubmed: 23983819
doi: 10.7150/jca.6888
pmcid: 3753529
Chen L, Chubak J, Boudreau DM, Barlow WE, Weiss NS, Li CI. Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-medicare population. Cancer Epidemiol Biomark Prev. 2017;26:1603–10.
doi: 10.1158/1055-9965.EPI-17-0346
Ganz PA, Habel LA, Weltzien EK, Caan BJ, Cole SW. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat. 2011;129:549–56.
pubmed: 21479924
doi: 10.1007/s10549-011-1505-3
pmcid: 3145014
Holmes S, Griffith EJ, Musto G, Minuk GY. Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study. Cancer Epidemiol. 2013;37:881–5.
pubmed: 24075077
doi: 10.1016/j.canep.2013.09.001
Kreklau A, Nel I, Kasimir-Bauer S, Kimmig R, Frackenpohl AC, Aktas B. An observational study on breast cancer survival and lifestyle related risk factors. Vivo. 2021;35:1007–15.
doi: 10.21873/invivo.12344
Musselman RP, Bennett S, Li W, Mamdani M, Gomes T, van Walraven C, et al. Association between perioperative beta blocker use and cancer survival following surgical resection. Eur J Surg Oncol. 2018;44:1164–9.
pubmed: 29858097
doi: 10.1016/j.ejso.2018.05.012
Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1:628–38.
pubmed: 21317458
doi: 10.18632/oncotarget.197
pmcid: 3248123
Sakellakis M, Kostaki A, Starakis I, Koutras A. β-Blocker use and risk of recurrence in patients with early. Breast Cancer Chemother. 2014;60:288–9.
Shah SM, Carey IM, Owen CG, Harris T, DeWilde S, Cook DG. Does beta-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharm. 2011;72:157–61.
doi: 10.1111/j.1365-2125.2011.03980.x
Wong MCS, Tam WWS, Lao X, Wang HHX, Kwan MWM, Cheung CSK, et al. The incidence of cancer deaths among hypertensive patients in a large Chinese population: a cohort study. Int J Cardiol. 2015;179:178–85.
pubmed: 25464439
doi: 10.1016/j.ijcard.2014.10.028
Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, et al. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat. 2013;140:567–75.
pubmed: 23912960
doi: 10.1007/s10549-013-2654-3
Liu D, Yang Z, Wang T, Yang Z, Chen H, Hu Y, et al. β2-AR signaling controls trastuzumab resistance-dependent pathway. Oncogene. 2016;35:47–58.
pubmed: 25798840
doi: 10.1038/onc.2015.58
Hiller JG, Cole SW, Crone EM, Byrne DJ, Shackleford DM, Pang JB, et al. Preoperative β-Blockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. Clin Cancer Res. 2020;26:1803–11.
pubmed: 31754048
doi: 10.1158/1078-0432.CCR-19-2641
Caparica R, Bruzzone M, Agostinetto E, De Angelis C, Fêde Â, Ceppi M et al. Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis. ESMO Open. 2021;6. https://doi.org/10.1016/j.esmoop.2021.100066 .
Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E. Prognostic and predictive impact of beta-2 adrenergic receptor expression in HER2-positive breast cancer. Clin Breast Cancer. 2020;20:262–73.
pubmed: 32229175
doi: 10.1016/j.clbc.2020.01.007
Hiller JG, Perry NJ, Poulogiannis G, Riedel B, Sloan EK. Perioperative events influence cancer recurrence risk after surgery. Nat Rev Clin Oncol. 2018;15:205–18.
pubmed: 29283170
doi: 10.1038/nrclinonc.2017.194
Creed SJ, Le CP, Hassan M, Pon CK, Albold S, Chan KT, et al. 2-adrenoceptor signaling regulates invadopodia formation to enhance tumor cell invasion. Breast Cancer Res. 2015;17:145.
pubmed: 26607426
doi: 10.1186/s13058-015-0655-3
pmcid: 4660629
Kim TH, Gill NK, Nyberg KD, Nguyen AV, Hohlbauch SV, Geisse NA, et al. Cancer cells become less deformable and more invasive with activation of β-adrenergic signaling. J Cell Sci. 2016;129:4563–75.
pubmed: 27875276
pmcid: 5201020
Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, et al. β-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. Cancer Res. 2017;77:5639–51.
pubmed: 28819022
doi: 10.1158/0008-5472.CAN-17-0546
pmcid: 5645237
Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here. Cancer. 2018;124:2086–103.
pubmed: 29424936
doi: 10.1002/cncr.31272
Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, et al. β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Br J Cancer. 2013;108:2485–94.
pubmed: 23695022
doi: 10.1038/bjc.2013.205
pmcid: 3694229
Gorre F, Vandekerckhove H. Beta-blockers: focus on mechanism of action. Which beta- blocker, when and why? Acta Cardiol. 2010;65:565–70.
pubmed: 21125979
doi: 10.1080/AC.65.5.2056244